Obrixtamig Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Obrixtamig comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Small Cell Lung Carcinoma. Most recent publication: Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas., Future Oncol, 2022.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
    Wermke M, Felip E, Gambardella V, et al. · Future Oncol · 2022
    PubMed: PMID 35815644 · NCT04429087 · Small Cell Lung Carcinoma

Publications by year

20222022: 1 publications.

2022
1

Publications by indication

Small Cell Lung Carcinoma (1)

  • Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
    Future Oncol · 2022 · PMID 35815644 · NCT04429087

Publications by journal

All Obrixtamig publications (1)

2022 (1 paper)

  1. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
    Wermke M, Felip E, Gambardella V, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35815644 · NCT04429087 · Small Cell Lung Carcinoma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).